Open AccessLow Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn’s Disease Patients
Author(s) -
Tanay Kaymak,
Federico Moriconi,
Jan Hendrik Niess,
Christoph Beglinger,
Petr Hrúz
Publication year - 2017
Publication title -
inflammatory intestinal diseases
Language(s) - English
Resource type - Journals
eISSN - 2296-9403
pISSN - 2296-9365
DOI - 10.1159/000486676
Subject(s) - medicine , discontinuation , gastroenterology , infliximab , refractory (planetary science) , crohn's disease , retrospective cohort study , surgery , disease , physics , astrobiology
Many patients with moderate to severe Crohn's disease (CD) are treated with infliximab (IFX). As most of these patients experience a long-lasting therapy, the outcome and withdrawal of IFX treatment are important clinical questions.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom